CD38 protein antibody and application thereof
US11713357B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 11, 2019 |
| Grant date | Aug 1, 2023 |
| Priority date | — |
| Expiry date | May 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.